Skip to content
Peptide research

Cartalax

Category
Bioregulators
Administration routes
InjectableOral
Regulatory status
Not FDA-approved

What it is

A synthetic tripeptide (Ala-Glu-Asp) marketed for joint and cartilage support, said to regulate genes in chondrocytes and osteoblasts tied to cartilage repair and bone formation. The case is mostly mechanistic and speculative, drawn from cell studies rather than human trials, so joint benefit claims remain unproven in people. There is essentially no human safety data, and supply is largely unregulated research-grade product. Not an approved drug in the US.

Read Full record

Studied uses & evidence

Studied uses(6)

  • Chondrogenic gene activation

    Speculative

    An indexed 2023 study found increased chondrogenic markers in aging human MSC cultures; clinical benefit remains unproven (PMID 37782646).

  • Anti-apoptotic effects in connective tissue

    Low

    Reduced apoptosis markers in human skin fibroblasts and rat kidney explants, not cartilage.

  • Extracellular matrix protection

    Low

    Single in vitro study found MMP-9 suppression in aging skin fibroblasts, not cartilage.

Evidence limits

Evidence Level
Preclinical

LIMITED. Evidence is primarily preclinical (in vitro cell culture studies). No large-scale randomized controlled trials in Western literature. Key evidence: (1) In vitro: AED at 200 ng/ml activates chondrogenic differentiation markers in aging human MSCs (Myakisheva et al., 2023). (2) In vitro: AED inhibits MMP-9 and caspase-3 while upregulating Ki-67 and CD98hc in aging skin fibroblasts (Linkova et al., 2016). (3) Molecular modeling: AED binds ACCT DNA sequence, providing mechanistic basis (Khavinson et al., 2016). (4) Systematic review confirms short peptides including AED regulate gene expression via DNA-peptide interactions (Khavinson et al., 2021). Russian clinical experience reports benefits in musculoskeletal conditions but lacks peer-reviewed controlled trial data accessible in Western databases.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(5)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Lack of large-scale clinical safety data

    High
  • Mild injection site reactions

    Low
  • Potential allergic reactions

    Low
  • Unregulated product quality

    High
  • Unknown long-term effects

    Moderate
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.